Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $78.70 USD
Change Today 0.00 / 0.00%
Volume 0.0
ENDP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Key Developments

Endo International Announces U.S. District Court Ruling Upholding OPANA ER Intellectual Property

Endo International plc announced that the U.S. District Court for the Southern District of New York has issued a ruling upholding two Endo patents covering OPANA® ER, the company's opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The ruling also determined that Endo's patents had been infringed by all of the defendants. As a result, it is expected that the generic version of non-crush-resistant OPANA® ER currently sold by Actavis, the U.S. generics business of Allergan Inc., will be removed from the market and additional approved but not yet marketed generic versions of the product developed by other generic companies will not be launched in the near term. In December 2012, Endo filed a patent infringement complaint against Actavis in U.S. District Court for the Southern District of New York for patent infringement based on Actavis' sale of a non-crush-resistant generic version of OPANA® ER. In 2013, Endo filed similar suits in the U.S. District Court for the Southern District of New York against the following additional applicants for non-crush-resistant OPANA® ER: Par Pharmaceutical, Teva Pharmaceuticals, Mallinckrodt LLC, Sandoz, Roxane and Ranbaxy. The suits against Par Pharmaceutical and Mallinckrodt LLC have been dismissed pursuant to settlements and the suits against Teva Pharmaceuticals and Sandoz have been dismissed based on those companies' demonstration to Endo that they do not intend to pursue an ANDA for non-crush-resistant OPANA® ER.

Endo International plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Affirms Earnings Guidance for the Full Year Ended December 31, 2015

Endo International plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $735.166 million, operating income of $1.490 million, loss from continuing operations before income tax of $103.614 million, loss from continuing operations of $90.894 million or $0.49 per diluted share, consolidated net loss of $250.526 million and net loss attributable to company of $250.419 million or $1.35 per diluted share against total revenues of $592.848 million, operating income of $111.059 million, income from continuing operations before income tax of $45.383 million, income from continuing operations of $40.575 million or $0.25 per diluted share, consolidated net income of $20.386 million and net income attributable to company of $21.160 million or $0.13 per diluted share a year ago. On Non-GAAP basis the company reported total revenues of $735.166 million, operating income of $297.483 million, income from continuing operations before income tax of $219.307 million, income from continuing operations of $204.335 million or $1.08 per diluted share, consolidated net income of $226.474 million and net income attributable to company of $226.581 million or $1.20 per diluted share against total revenues of $592.848 million, operating income of $233.632 million, income from continuing operations before income tax of $187.541 million, income from continuing operations of $147.286 million or $0.86 per diluted share, consolidated net income of $174.852 million and net income attributable to company of $173.682 million or $1.06 per diluted share a year ago. For the six months, the company reported total revenues of $1,449.294 million, operating income of $47.237 million, loss from continuing operations before income tax of $119.991 million, loss from continuing operations of $59.598 million or $0.33 per diluted share, consolidated net loss of $326.244 million and net loss attributable to company of $326.137 million or $1.78 per diluted share against total revenues of $1,063.690 million, operating income of $132.941 million, income from continuing operations before income tax of $10.685 million, loss from continuing operations of $6.826 million or $0.04 per diluted share, consolidated net loss of $412.892 million and net loss attributable to company of $415.752 million or $2.96 per diluted share a year ago. On Non-GAAP basis the company reported total revenues of $1,449.294 million, operating income of $615.132 million, income from continuing operations before income tax of $467.057 million, income from continuing operations of $411.695 million or $2.25 per diluted share, consolidated net income of $454.489 million and net income attributable to company of $454.596 million or $2.49 per diluted share against total revenues of $1,063.690 million, operating income of $413.259 million, income from continuing operations before income tax of $326.153 million, income from continuing operations of $255.763 million or $1.65 per diluted share, consolidated net income of $312.551 million and net income attributable to company of $307.747 million or $1.99 per diluted share a year ago. Net cash used in operating activities was $77.486 million against $52.631 million a year ago. Purchases of property, plant and equipment, net was $38.621 million against $40.379 million a year ago. For the year ended December 31, 2015, the company estimates total revenue to be between $2.90 billion and $3.00 billion, reported (GAAP) diluted earnings per share (EPS) from continuing operations now expected to be between $1.42 and $1.62 compared to $1.70 and $1.90 previously, adjusted gross margin of between 64% and 65%, adjusted effective tax rate of between 13% and 14%, adjusted diluted earnings per share from continuing operations assume full year adjusted diluted shares outstanding of approximately 180 million; and full-year 2015 financial guidance excludes the impact of the pre-close financing activities related to the acquisition of Par.

Endo International plc to Report Q2, 2015 Results on Aug 10, 2015

Endo International plc announced that they will report Q2, 2015 results Pre-Market on Aug 10, 2015

Endo International plc, Q2 2015 Earnings Call, Aug 10, 2015

Endo International plc, Q2 2015 Earnings Call, Aug 10, 2015

Endo International plc Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 03:00 PM

Endo International plc Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 03:00 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Rajiv Kanishka Liyanaarchchie De Silva, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $78.70 USD 0.00

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.131.30 CHF +1.00
CR Bard Inc $197.47 USD 0.00
Edwards Lifesciences Corp $144.70 USD 0.00
Hospira Inc $89.93 USD 0.00
UCB SA €67.14 EUR -0.39
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.